Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Albano Del Favero"'
Autor:
Paul J. Hesketh, Sussanne Börjeson, Mark G. Kris, Jim M. Koeller, Ian N. Olver, Lawrence H. Einhorn, Jørn Herrstedt, Matti Aapro, Alex Molassiotis, Albano Del Favero, Rebecca Clark-Snow, Steven M. Grunberg, Richard J. Gralla, Cynthia N. Rittenberg, David Osoba, Maurizio Tonato, Fausto Roila, Enzo Ballatori, Petra Feyer, Rolf Kaiser, David Warr, Ernesto Maranzano, Bernardo Leon Rapoport
Publikováno v:
Annals of Oncology. 17:20-28
In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analyses of the available published trials and provided nearly similar
Autor:
Albano Del Favero, Cecilia Caramatti, Marco Picardi, Morena Caira, Gimema Infection Program, Livio Pagano, Saverio Cinieri, Giulio Trapè, Rossana Putzulu, Annamaria Nosari
Publikováno v:
Annals of Hematology. 83:592-595
Toxoplasmosis is one of the most common parasitic infections in humans, but in most cases it does not cause serious illness; this protozoan can nevertheless cause devastating disease in immunocompromised hosts such as HIV-positive individuals. Only r
Autor:
Agostino Cortelezzi, Bernardino Allione, Luca Mele, Massimo Offidani, Bruno Martino, Luana Fianchi, Giuseppe Milone, Pietro Martino, Corrado Girmenia, Annamaria Nosari, Francesco Fabbiano, Cecilia Caramatti, Paolo Ricci, Marco Picardi, Luciano Masini, Albano Del Favero, Maria A. Cappucci, Paolo Piccaluga, Massimo Buelli, Rosangela Invernizzi, Livio Pagano, Giuseppe Todeschini, Laura Corvatta, Maria Enza Mitra, Domenico Russo
Publikováno v:
British Journal of Haematology. 117:379-386
A retrospective survey was conducted over a 10-year period (1990-99) among 52 haematology divisions in order to evaluate the clinical and laboratory characteristics and outcome of patients with proven Pneumocystis carinii pneumonia (PCP) complicating
Publikováno v:
The Lancet Infectious Diseases. 2:231-242
We set out to compare the efficacy of antibiotic monotherapy with that of combination therapy including an aminoglycoside for empirical treatment of febrile neutropenic cancer patients. We did a meta-analysis of 29 randomised clinical trials pooling
Purpose A combination of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone is recommended for the prophylaxis of acute or delayed emesis induced by chemotherapy containing anthracyclines plus cyclophosphamide in patients with breast cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6bb3ebe49ad29aab3bdef09a1827262
http://hdl.handle.net/11391/1502712
http://hdl.handle.net/11391/1502712
Autor:
Monica Bocchia, Laura Cudillo, Anna Chierichini, Massimo Offidani, Rosa Fanci, Francesco Fabbiano, Nicola Cascavilla, Bruno Martino, Giovanni Martinelli, Giuseppe Gentile, Robin Foà, Annunziata Manna, Antonella Ferrari, Mario Luppi, Giorgina Specchia, Giovanni Quarta, Valeria Primon, Giuseppe Milone, Giampaolo Bucaneve, Marco Picardi, Albano Del Favero, Stelvio Ballanti, Eliana Zuffa, Prassede Salutari, Renato Cantaffa, Alessandra Micozzi
Purpose Empiric antibiotic monotherapy is considered the standard of treatment for febrile neutropenic patients with cancer, but this approach may be inadequate because of the increasing prevalence of infections caused by multidrug resistant (MDR) ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f07ffc90d182dc41e65a1edcbc76820
https://hdl.handle.net/11380/1070270
https://hdl.handle.net/11380/1070270
Autor:
Pietro Martino, Gruppo Italiano Malattie Ematologiche dell'Adulto (Gimema) Infection Program, Giampaolo Bucaneve, Alessandra Micozzi, Albano Del Favero, Giuseppe Gentile, Francesco Menichetti, Domenico Russo, Paolo Ricci, Franco Mandelli, Domenico D'Antonio, Bruno Martino, Paolo Furno
Publikováno v:
Clinical Infectious Diseases. 33:1295-1301
In a prospective, multicenter, double-blind, randomized clinical trial, we compared the efficacy of piperacillin-tazobactam (4.5 g 3 times daily intravenously) plus placebo versus piperacillin-tazobactam plus amikacin (7.5 mg/kg twice daily intraveno
Autor:
Corrado Girmenia, Livio Pagano, Laura Corvatta, Luca Mele, Albano Del Favero, Pietro Martino for the Gimema Infection Pr
Publikováno v:
British Journal of Haematology. 111:272-276
Publikováno v:
PharmacoEconomics. 15:85-95
Objective: Patients with cancer-associated neutropenia are at high risk of developing severe infections which can be fatal if treatment is not promptly administered. For this reason, fever is treated as soon as possible with broad spectrum antibacter
Publikováno v:
Drug Safety. 9:410-428
Nausea and vomiting are among the most distressing adverse effects of cancer chemotherapy. In the last 10 years considerable advances in the prevention of chemotherapy-induced emesis have been made. From an analysis of the results obtained in patient